India's Alzheimer's treatment landscape has been enhanced with the introduction of Lormalzi (donanemab), a therapy that aims to slow the progression of the disease by targeting amyloid plaques in the brain. Approved for patients with mild cognitive impairment (MCI) or mild dementia, Lormalzi is most effective when administered early, before significant brain damage occurs. However, neurologists caution that it is not suitable for everyone. Patients with advanced dementia, certain vascular conditions, or those at risk of brain bleeding may not benefit from the treatment. Regular MRI monitoring is essential to detect potential amyloid-related imaging abnormalities (ARIA), which can include brain swelling and bleeding. As India anticipates a rise in dementia cases, understanding who can safely benefit from therapies like Lormalzi is critical. While it represents a significant step forward in Alzheimer's care, it is not a cure and should be part of a broader treatment approach that includes lifestyle changes and caregiver support.